Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | July 31, 2018 |
| Target | TiGenix N.V. |
| Sector | Life Science |
| Buyer(s) | Takeda |
| Deal Type | Add-on Acquisition |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1781 |
| Sector | Life Science |
| Employees | 47,455 |
| Revenue | 4.58T JPY (2025) |
Takeda is a global biopharmaceutical organization committed to improving the health and well-being of people worldwide. Takeda is dedicated to addressing unmet medical needs through the development of innovative and transformative therapies. The Company's diverse portfolio encompasses a wide range of therapeutic areas, including oncology, gastroenterology, rare diseases, neuroscience, and vaccines. Takeda was established in 1781 and is based in Tokyo, Japan.
| Deal Context for Buyer | # |
|---|---|
| Overall | 12 of 18 |
| Sector: Life Science | 11 of 17 |
| Type: Add-on Acquisition | 11 of 15 |
| Country: Belgium | 1 of 1 |
| Year: 2018 | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-05-08 |
Shire
Dublin, Ireland Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest. |
Buy | £44.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-05-09 |
Xiidra
Basel, Switzerland XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease. Xiidra is based in Basel, Switzerland. |
Sell | - |
